An integrative method for scoring candidate genes from association studies: application to warfarin dosing

BMC Bioinformatics

Volumn 11, Issue SUPPL. 9, 2010, Pages

  Tatonetti, Nicholas P ^a,b   Dudley, Joel T ^a   Sagreiya, Hersh ^a   Butte, Atul J ^a   Altman, Russ B ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanford University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECT; AGGREGATION METHODS; CANDIDATE GENES; DRUG RESPONSE; KNOWLEDGE INTEGRATION; KNOWLEDGE SOURCES; LOGISTIC REGRESSION CLASSIFIER; PHARMACOGENOMICS;

DNA SEQUENCES;

GENES;

ANTICOAGULANT AGENT; CYTOCHROME P 450 CYP2C SUBFAMILY; CYTOCHROME P-450 CYP2C SUBFAMILY; CYTOCHROME P450; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; WARFARIN;

ARTICLE; DOSE RESPONSE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETICS; GENOTYPE; METHODOLOGY; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL;

ANTICOAGULANTS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE FREQUENCY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; LOGISTIC MODELS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 78049469951     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-11-S9-S9     Document Type: Article

References (18)

1. Guessous I, Gwinn M, Khoury MJ. Genome-wide association studies in pharmacogenomics: untapped potential for translation. Genome Med 2009, 1(4):46. 10.1186/gm46, 2684667, 19439031.
2. Gurwitz D, Mcleod HL. Genome-wide association studies: powerful tools for improving drug safety and efficacy. Pharmacogenomics 2009, 10(2):157-159. 10.2217/14622416.10.2.157, 19207015.
3. Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008, 359(8):789-799. 10.1056/NEJMoa0801936, 18650507.
4. Sato Y, Laird NM, Nagashima K, Kato R, Hamano T, Yafune A, Kaniwa N, Saito Y, Sugiyama E, Kim S-R, et al. A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies. The Pharmacogenomics Journal 2009, 9(2):137-146. 10.1038/tpj.2008.17, 19104505.
5. Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T, Takahashi N, Ozaki N, Arinami T. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 2008, 18(4):317-323. 10.1097/FPC.0b013e3282f70492, 18334916.
6. Askland K, Read C, Moore J. Pathways-based analyses of whole-genome association study data in bipolar disorder reveal genes mediating ion channel activity and synaptic neurotransmission. Hum Genet 2009, 125(1):63-79. 10.1007/s00439-008-0600-y, 19052778.
7. Crowley J, Sullivan P, McLeod H. Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics 2009,
8. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Archives of Internal Medicine 2005, 165(10):1095-1106. 10.1001/archinte.165.10.1095, 15911722.
9. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005, 352(21):2211-2221. 10.1056/NEJMra032424, 15917386.
10. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002, 12(3):251-263. 10.1097/00008571-200204000-00010, 11927841.
11. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005, 105(2):645--649. 10.1182/blood-2004-06-2111, 15358623.
12. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008, 111(8):4106-4112. 10.1182/blood-2007-11-122010, 2288721, 18250228.
13. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. The Pharmacogenomics Journal 2005, 5(4):262-270. 10.1038/sj.tpj.6500313, 15883587.
14. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009, 5(3):e1000433. 10.1371/journal.pgen.1000433, 2652833, 19300499.
15. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008, 112(4):1022-1027. 10.1182/blood-2008-01-134247, 2515139, 18535201.
16. Consortium IWP, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee M-TM, Limdi NA, Page D, Roden DM, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 360(8):753-764. 10.1056/NEJMoa0809329, 2722908, 19228618.
17. Hansen NT, Brunak S, Altman RB. Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther 2009, 86(2):183-189. 10.1038/clpt.2009.42, 2729176, 19369935.
18. McCarthy JJ, Hilfiker R. The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 2000, 18(5):505-508. 10.1038/75360, 10802616.